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Abstract. The objectives of this analysis were an 
assessment of the feasibility of a more individually 
tailored approach of empirical antibiotic therapy in 
febrile neutropenia and an exploration of the reasons 
to modify the initial regimen.
Design, setting and subjects. The main source was a 
database on febrile neutropenic cancer patients from 
an unblinded large trial conducted in 35 centres 
world-wide. This was supplemented by data from 
patients enrolled in a consecutive series of random­
ized trials at the Department of Haematology, 
University Hospital Nijmegen,
Interventions. Diagnostic procedures were standard­
ized, types of possible infections defined and the reasons 
for modifying an empirical regimen were recorded. 
Main outcome measures. Survival of the febrile 
neutropenic episode, development of microbiologi- 
cally and clinically defined infection in relation to
causative organisms, and results of modification. 
Results. Monotherapy was as effective as combination 
therapy with an overall mortality of <7%, with 2 1 % 
of neutropenic episodes accompanied by a clinically 
defined infection proving fatal compared with only 
4% of episodes without a focus. At the end of treat­
ment the empirical regimen had been added to in 60% 
of cases in the multicentre trial, in contrast to 39% in 
our own institution, in many cases simply because of 
continuing fever.
Conclusion. The development of local guidelines for 
individually tailoring antibiotic therapy by comple­
menting the empirical regimen is a feasible option for 
achieving an optimal anti-infective strategy for febrile 
neutropenic cancer patients.
Keywords: bone-marrow transplantation, empirical 
antibiotics, fever, infection, leukaemia, neutropenia.
Introduction
Aggressive bone-marrow ablative chemotherapy and 
bone-marrow transplantation have become acceptable 
treatment options for patients with an otherwise incur­
able malignant disease. However, profound and pro­
longed neutropenia occurs which carries with it an 
inherent risk of life-threatening infection necessitating 
the implementation of appropriate anti-infective strat­
egies in institutes which care for such patients. As 
neutropenic patients are unable to produce an ade­
quate inflammatory response, any fever that develops 
should be considered to be due to infection until proven 
otherwise. Early mortality due to infection has been 
reduced by the universal adoption of the so-called 
empirical approach whereby broad spectrum antibi­
otics are given in order to provide protection against the 
fulminant infection due to Gram-negative bacilli [1].
Traditionally, empirical regimens have consisted of 
a combination |3~Iactam and an aminoglycoside and 
discussions about the number and kinds of antibiotics 
still lingers on [2]. The results of many of the older 
studies are now outdated due to changes in the spec­
trum  of micro-organisms causing infection in neutro­
penic patients as well as in the management of 
malignant diseases. Besides the obvious variation 
between hospitals in the most prevalent pathogens, 
there has been a major shift from Gram-negative to 
Gram-positive bacterial pathogens as well as a shift in 
the relative frequency of individual Gram-negative 
bacillary species particularly Pseudomonas aeruginosa. 
This phenomenon is thought to be the combined 
result of the selective pressure of prophylactic anti­
microbial regimens of the commensal flora, the 
disruption of physical barriers by indwelling intra- 
vascular catheters, such as the Hickman tunnelled
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catheter, and the mucosal damage induced by more 
aggressive cytotoxic therapy. The constitution of the 
optimal empirical regimen remains an issue because 
of the change in the spectrum of pathogens, the avail­
ability of novel antibiotics and flaws in the clinical 
trials published hitherto. The major randomized trials 
of the last decade failed to show any substantial differ- 
ence between the efficacy of the antibacterial agents 
compared. There are no reasons for thinking that this 
will change in the future due to the fact that fever was 
unexplained in the majority of episodes treated and 
actually represented a low enough risk that using any 
of the modern potent antibacterial agents would vir­
tually guarantee success. Analysing the various risk 
groups separately is usually frustrated by a lack of 
sufficient numbers to allow reliable conclusions. 
Nevertheless, common sense dictates that it must be 
possible to achieve an approach more tailored to the 
empirical treatment of the individual febrile neutro­
penic patients. This is borne out by circumstantial evi­
dence as patients with a clinically manifest focus of 
infection clearly represent a different population than 
do those in whom a site is not detected. Local circum­
stances are already accepted as a basis for individual­
izing treatment but the sites of infection that are 
present at the onset of fever have been largely ignored 
even though they can provide an important clue as to 
the causative agent.
It is remarkable that studies published on the man­
agement of infectious complications in neutropenic 
patients focus almost entirely on the empirical phase 
of treatment, i.e. the first 3-4 days after the onset of 
fever. Few details are provided on the complications 
that occur afterwards even though a considerable 
number of patients do not respond completely to the 
empirical treatment. This makes modification of 
treatment the rule rather than the exception in pro­
longed neutropenia [3,4]. As mentioned earlier, the 
origin of fever remains obscure in a substantial num­
ber of cases making rational decisions on subsequent 
antimicrobial treatment difficult, which is precisely 
why the large multicentre randomized studies can 
send the practising physician along the wrong track. 
For instance, when confronted with persisting fever in 
a stable neutropenic patient one doctor may perceive 
the need to adjust the empirical regimen, while his 
colleague is more confident and is prepared to wait for 
the results of diagnostic tests. In terms of trial out­
come, the first case would be deemed a failure and the 
second a success. Thus, not only are the antibiotics on
trial but so too are the doctors which means that the 
final results of the study depend heavily on the 
behaviour of the physicians involved [5]. This need 
not be a problem provided that the reasons for modifi­
cation are reported in detail. Unfortunately, this is 
rarely the case so the reader must read the report 
thoroughly if he is to put the seemingly objective 
results into perspective and avoid drawing the wrong 
conclusions. Indeed, if no guidelines for adjusting 
empirical regimen are available, it will be almost 
inevitable that antibiotics will be overused and chosen 
in a haphazard fashion particularly if there are no 
local guidelines or policies for prescribing antibiotics.
The aim of the present paper is to provide argu­
ments for an individual approach to the treatment of 
infection in the neutropenic patient and a strategy for 
both the empirical and subsequent antimicrobial 
treatment using the results of a series of prospective 
trials on the efficacy and safety of broad-spectrum 
antibiotic empirical regimens.
Patients and methods
Patients
The database on patients recruited to a large multi­
centre trial [4,6,7] of the empirical management of 
febrile neutropenic patients was the main source of data 
for analysing factors that might predict the outcome of 
empirical antibiotic therapy. This was supplemented by 
the data from a consecutive series of randomized trials 
conducted at our own institution [8-18].
Diagnostic procedures
Fever was defined as a single axillary temperature of 
38.5°C or at least two readings of >38°C taken 2 h 
apart. Patients aged >14 years suffering from a 
haematological malignancy were included provided 
that intensive chemotherapy had induced neutro­
penia with granulocyte counts of <0.5 x 109/L, 
Therapy was started once a comprehensive clinical 
examination of the skin, oral cavity and perianal 
region had been completed, a chest radiograph had 
been made and tests for laboratory investigations had 
been taken. Ten millilitres of blood were obtained for 
culture from each of two separate veins and another 
10 mL were taken via a central venous catheter when 
present. A specimen of urine was obtained for culture 
as were other appropriate specimens from any local 
site of infection when present. Isolates were identified
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and their antimicrobial susceptibility was determined 
using standard techniques. Patients were examined 
daily with special attention being paid to detecting 
possible sites of infections of the lungs, perianal area, 
central venous catheter exit site and tract, skin, and 
oral cavity. In most cases, further specimens of blood 
and urine were obtained for culture and a chest radio­
graph was taken 72 h after start of treatment and 
when a change in antimicrobial therapy was consid­
ered necessary by the physician in charge. Invasive 
diagnostic techniques such as bronchoalveolar lavage 
were performed on a case-by-case basis. Biochemical 
profiles were determined once weekly and haemato- 
logical profiles at least three times weekly.
Definitions
Clinical sepsis was characterized by a sudden rise in 
temperature to at least 39 °C, accompanied by rigors 
and/or chills, tachycardia, tachypnoea, or malaise 
with or without hypotension. The detection of a pul­
monary infiltrate on the chest radiograph or physical 
abnormalities consistent with a pulmonary infiltrate 
was considered to represent a lower respiratory tract 
infection unless a non-infectious origin had been 
established. Ulceration of the skin, pyodermatitis, or 
cellulitis constituted a skin and soft-tissue infection 
and was deemed to be related to the intravascular 
catheter when inflammation or tenderness was 
present around its exit site or along its track or when a 
seropurulent exudate was produced. As it is all but 
impossible to distinguish between mucositis and 
infection, any complaints of local pain accompanying 
ulceration, erythema, tenderness, swelling or pseudo­
membranes in the throat, nose or oral cavity were 
deemed an upper respiratory tract infection. Similarly, 
abdominal pain and tenderness, diarrhoea or abnor­
malities found on an abdominal ultrasound or CT- 
scan that suggested a lesion, represented gastro­
intestinal infection unless they could be clearly 
attributed to cytotoxic chemotherapy. Urinary tract 
infection was defined by painful micturition and bac- 
teriuria of >105 cfu/mL urine. Death was attributed 
to i-nfection when it occurred as a direct consequence 
of either the presenting or subsequent infection.
Classification of infection
Fever was attributed to a microbiologically defined 
infection (MDI) when bacteraemia was detected in at 
least one blood culture yielding any bacterium except
coagulase-negative staphylococci and skin coryne- 
forms for which two identical cultures of blood 
obtained within 2 h of each other were necessary. The 
cause of fever accompanied by a focus of infection 
was deemed a clinically defined infection (CDI) unless 
a micro-organism other than commensal flora had 
been isolated in which case it was considered an MDI. 
All other fevers were considered unexplained if nei­
ther a CDI nor MDI had been determined within the 
first 72 h after starting empirical treatment. Any new 
infective event that occurred during or after stopping 
treatment was classified as a subsequent infection.
Modifications to therapy
Data from the patients who were enrolled in random­
ized trials at our own institute were used to assess the 
adherence of clinicians to a set of rules that provided 
guidance for modifying initial therapy by addition or 
substitution. Briefly, these were deterioration of vital 
signs, progression of an existing CDI during persisting 
neutropenia, persistence of a presumed pathogen, iso­
lation of pathogen resistant in vitro to the empirical 
regimen in the absence of clinical improvement, 
occurrence of a new MDI, CDI or episode of unex­
plained fever, unexplained fever persisting for more 
than 5 days, and adverse drug reactions attributable to 
an empirical antibiotic [19]. The reasons for altering 
therapy were recorded in the patient's case notes or the 
case report form. A change in therapy made according 
to these guidelines was considered to be an objectively 
verifiable reason for modification. All other changes in 
antibiotic therapy, including the cases where no clear 
explanation could be found in the case notes, were cat­
egorized as subjective reasons for modification. Dosage 
adjustments and replacing the empirical regimen with 
oral prophylaxis were not considered to be modifica­
tions. A change in therapy during the first 72 h was 
defined as an early modification.
Discontinuation of empirical therapy
Broad-spectrum antimicrobial coverage was to be dis­
continued once the granulocyte count had risen to 
>0.5 x 109/L and there had been no signs and symp­
toms of infection for at least 2 days or for at least 5 
consecutive days when neutropenia persisted.
Classification of outcome
Clinical outcome was evaluated according to the 
criteria of Pizzo and co-workers [3]: 'Success without
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modification' was applied to any neutropenic episode 
which the patient survived and became free of all 
signs and symptoms of infection with a return of the 
temperature to below 3 7.5°C for at least 2 days with­
out modifying the initial empirical regimen. ‘Success 
with modification’ referred to any patient who sur­
vived the neutropenic episode but for whom empiri­
cal therapy had been changed in any way other than 
a dosage adjustment. Patients who died because of 
infection were regarded as ‘failures’. Each episode of 
empirical treatment was evaluated after 72 h of 
therapy and at the end of treatment.
Table 2 Survival of bacteraemia in the multicentre trial
Piperacillin- 
Ceftazidime tobramycin
Assessable febrile episodes 389 395
Bacteraemias 163 173
Gram-negative 62 61
« Survived primary infection 92% 93%
0 Ultimate survivors 87% 79%
Gram-positive 101 112
0 Survived primary infection 98% 95%
•  Ultimate survivors 91% 87%
Clinically defined infections 41 41
Results
Outcome of empiric therapy
The demographic characteristics of the study popu­
lation are given in Table 1. Monotherapy was shown 
to be as effective as a traditional combination of a
Table 1 Demography of the study population in the multicentre 
trial and retrospective survey
Piperacillin* Retro­
spective
surveyCeftazidime Tobramycin
Assessable febrile 
episodes
389 395 1951
Males/females 224/165 204/191 1112/839
Mean age (years) 
Underlying diseases
44.5 45,4 44
Haematological
malignancies
314(80%) 316(80%) 1389(71%)
Solid tumours 14(4%) 24(6%) 117(6%)
Bone marrow 
transplants 
Gr anu lo cy topenia
61(16%) 55(14%) 445(23%)
Days granulocytes 
<0.5 x 1Q9/L
18 + 1.5 18 ± 1.5 22 ± 2
Days granulocytes 
< 0 .1 x 109/L 
Empirical regimens
13 + 1.3 13 ± 1.1 14 ± 1
Monotherapy 389 0 1446(75%)
Aminoglycoside
combinations
0 395 245(13%)
Double p-lactam 
combination
---------- — - 100(5%)
Glycopeptide
combinations
— — > 140(7%)
Cephalosporin*
lincosamide
20(1%)
broad spectrum penicillin and an aminoglycoside. 
At the end of treatment with ceftazidime, 35% of 
episodes were registered as successes, 60% of cases 
survived the neutropenic episode after the addition 
of other antibiotics, while 6 % of patients died of 
infection. Success was achieved in 33% of episodes 
treated with piperacillin plus tobramycin, additional 
antimicrobials were given in 59% and 8% died of 
infection. Even within the various subgroups, 
including Gram-negative bacteraemias, no differ­
ences were found (Table 2, Fig. 1). In a retrospective 
analysis the success of monotherapy in treating 
infection due to Gram-negative bacilli was con­
firmed with eradication being achieved in 179 out of 
201 (89%) cases, including 50 out of 57 (8 8%) due 
to Pseudomonas aeruginosa.
Overall
Leukaemia 
Solid tumour
Unexplained fever 
Clinical infection 
Microbiology positive 
Bacteraemia
Anaerobic 
Skin and soft tissue
None
Focus 
No focus
Bacteraemia 
No bacteraemia
Gram negatives 
Gram positives 
Polymicrobial
Favours
ceftazidime
0 1
Fig. 1 Odds ratios of efficacy of two regimens in various subgroups 
of infection.
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Relation symptoms of infection and causative micro­
organisms
In the multicentre randomized trial 113 additional 
patients at high risk of Gram-positive infection, 
namely those with skin and soft tissue infection such 
as cellulitis and catheter-related infections, were 
given vancomycin from the start to supplement the 
core regimens. A higher proportion of patients, allo­
cated to receive vancomycin from the beginning, had 
Gram-positive bacteraemia (31%) than did those 
given the core regimens alone (19%), indicating that, 
to a certain extent, it is possible to predict the occur­
rence of a Gram-positive organism as cause of the 
infection. This prospective finding corroborates the 
observation from the retrospective survey where sites 
of infection provided a clue to the infecting organism. 
Many skin and soft-tissue infections were associated 
with prosthetic devices involving mainly slime-pro­
ducing strains of coagulase-negative staphylococci. 
Upper respiratory tract infections featured Candida 
albicans, herpes simplex virus, viridans streptococci, 
enterococci or anaerobes. Bacterial infections, includ" 
ing those due to Gram-negative bacilli, accounted for 
most pulmonary infiltrates that appeared as segmen­
tal shadows whilst the majority of the focal 
pulmonary infiltrates were caused by fungi, Diffuse 
pulmonary infiltrates were related to adult respira­
tory distress syndrome (ARDS) following bacteraemia 
w ith viridans streptococci, pulmonary haemorrhage, 
infection due to Pneumocystis carinii, and, in bone- 
m arrow  transplant recipients, cytomegalovirus infec­
tion. Urinary tract infections seldom occurred and 
usually involved Gram-negative bacilli. In the retro­
spective series, the outcome of 7% of neutropenic 
episodes overall proved fatal but included 2 1 % of 
episodes complicated by a CDI compared with 4% for 
episodes in which no focus of infection was identified. 
Pulmonary infiltrates accounted for most of the 
deaths, as 28% died in contrast to 7% of patients with 
another focus of infection.
At the onset of fever, clinical sepsis was present in 
8%, a CDI in 29%, and 63% showed neither local nor 
systemic signs and symptoms of infection. Early 
changes in therapy, i.e. within 72 h, were considered 
necessary in 11% of cases. After this time, the num­
ber of patients without either a CDI or MDI had 
decreased to 41%, primarily because the results of the 
blood cultures had become available and revealed that 
bacteraemia had accompanied 19% of episodes at the 
onset of fever without evidence of clinical sepsis. New 
foci of infection had emerged in 1 2% of cases, mainly 
of the lungs. The increase in the number of lower res­
piratory tract infections was based on new pul­
monary infiltrates on the follow-up chest radiograph.
Modification o f the empirical regimen
\y the end of the truly empirical phase the clinical con­
dition had deteriorated in 10% of patients, improved in 
25%, and was stable in 65% (Fig. 2). Deterioration was 
most prominent in patients with bacteraemia due to 
Gram-negative bacilli CDIs, whereas patients with unex­
plained fever showed improvement or were in a stable
»II
G-ve bactaeremia 
|fH other bactaeremia 
□  CDI
E3 unexplained fever
Improving
25%
n s=- 1085
Stabl e 
65%
Deteriorating
10%
Fig. 2 Change of clinical 
condition after 3 days in relation 
to causative organisms and 
ultimate outcome.
% afebrile after 5 days 100 
% ultimately survived 100
33
90
5
11
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condition, in contrast to the multicentre trial where 
antibiotics had been added in 60% of cases at the end of 
treatment, the empirical regimens were modified in 3 9 % 
of the 1951 cases at our own institution. Seventy-six 
per cent of the latter modifications were classified as 
objectively verifiable. In patients with a lower respiratory 
tract infection the modification rate was to 69%, whilst 
adjustments were deemed necessary in 51% of cases 
with a skin and soft tissue infection, in 44% of the febrile 
episodes accompanied by abdominal complaints, and in 
37% of the upper respiratory tract infections. 
Glycopeptides were used in 22% to complement the 
empirical regimen. However, empirical administration 
of teicoplanin for continuing fever alone resulted in a 
response in 33%, whereas 94% of patients with a per­
sisting Gram-positive responded. The addition of an 
aminoglycoside to ceftazidime was thought necessary in 
only 8% of cases and systematically active antifungal 
agents were administered in 16% of cases.
Discussion
Numerous antibiotics, given alone or in combination 
have been tested in many trials on empirical antibiotic 
therapy but no superior regimen has been established. 
Three different basic strategies are presently recom­
mended [2 ]: 1) a combination of a (3-lactam with an 
aminoglycoside; 2) two (3-lactam antibiotics; or 
3) monotherapy with an extended spectrum (3-lac­
tam. Monotherapy is readily acknowledged to consti­
tute adequate empirical treatment for unexplained 
fevers without prolonged neutropenia, but concern 
has been expressed about relying solely on a single 
agent for empirical antibiotic treatment. Indeed, most 
of the randomized controlled trials of empirical 
monotherapy, employing ceftazidime or imipenem- 
cilastatin, enrolled too few patients to allow a definite 
conclusion, although monotherapy did not lead to 
excess mortality, either overall or in infections caused 
by Gram-negative bacilli. In the meantime, larger 
studies, comprising a sufficient number of serious 
infections in high-risk patients, such as those who 
were treated for haematological malignancies, have 
shown equivalent efficacy in comparison with more 
traditional combinations [4,20,21]. Monotherapy 
was associated with fewer adverse events and 
appeared more cost-effective. The main objection to 
this approach is based on the conclusions of the 
Antimicrobial Study Group of the European Organ­
isation for Research and Treatment of Cancer
(EORTC) in whose trial ceftazidime in combination 
with 3 days of amikacin was significantly less effective 
than ceftazidime in combination with a full course of 
amikacin, particularly in the treatment of Gram- 
negative infections [5]. However, the alleged superior­
ity of the full course amikacin arm only became 
apparent after 3 days, a remarkable observation since, 
until that moment, both groups had been treated with 
an identical regimen and only afterwards did one of 
the groups receive monotherapy, This finding can be 
explained by the need for an additional antibiotic for 
fever persisting for more than 3 days was considered a 
failure in this trial, whereas the median duration of 
fever in serious infections, even with adequate antibi­
otic therapy is 4-5 days [4,22], The fact that the puta­
tive difference occurred at the third and crucial day of 
this unblinded trial suggests that the views of the doc­
tors towards treating serious infections with a single 
agent nuiy well have exerted considerable influence. 
Moreover, the striking rate of defervescence in the full 
combination arm was never seen by other investiga­
tors, nor could it be reproduced by the EORTC itself 
[21,23] in later studies (Table 3).
With the variation in prevalent organisms and the 
availability of very broad-spectrum antibiotics it may 
be time to abandon the standard approach and insti­
tute a more individually tailored one (Table 4). 
Patients with a catheter-associated infection or other 
infections of the skin and soft tissues might benefit 
from complementing empirical therapy with a glyco- 
peptide. If there is reason to suspect the presence of a
Table 3 Persistence of fever in relation to ultimate outcome of 
Gram-negative bacteraemias
Study
Percentage 
of patients 
with fever 
at day 3
Successful 
outcome at 
the end of 
treatment
EORTC 1987 [5]
Ceftazidine + short course amikacin 36% 48%
Ceftazidine + full course amikacin 11% 81%
EORTC 1995 [21]
Ceftazidine + full course amikacin 60% 62%
Piperacillin-tazobactam + amikacin 55% 75%
EORTC 1996 [23]
Ceftazidine + full course amikacin 65% 54%
Meropenem alone 60% 70%
Intercontinental Study Group 1994 [4]
Ceftazidine alone 55% 95%
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Table 4 Individually tailored empirical antibiotic therapy, University Hospital Nijmegen
Clinical situation
Concurrent diseases
• Impaired kidney function
• Allergy for a given antibiotic
• Heart dysfunction
Concomitant potentially nephro-and ototoxic drugs 
Colonization by resistant organism
No focus of infection present
• Slow onset of fever
• Sudden onset of fever
Focus of infection present
• Upper respiratory tract
• Lower respiratory tract
•  Skin and soft tissue (including central venous line)
•  Urinary tract
• Abdominal symptoms
methicillin-resistant Staphylococcus aureus on the 
basis of local patterns of resistance, a glycopeptide 
should be included in the initial regimen, Supple­
m enting empirical therapy with early antifungal 
therapy seems warranted in patients with focal pul­
m onary infiltrates. However, in very severe cases of 
oropharyngeal infection, early use of specific agents 
such as clindamycin or fluconazole if there is any 
extension to the oesophagus manifest by retrosternal 
pain, may result in lower morbidity. Patients who 
receive other potentially nephrotoxic drugs simultan­
eously are primary candidates for empirical therapy 
w ith ceftazidime or meropenem as a single agent. 
Considering the probable involvement of anaerobes, a 
carbapenem or the addition of metronidazole to a 
standard anti-Gram-negative regimen are logical 
choices when fever is accompanied by abdominal 
symptoms. Patients who are known to be colonized by 
resistant Gram-negative bacilli require coverage with 
two appropriate antibacterial agents that do not 
exhibit cross-resistance. Occurrence of sepsis syn­
drome often reflects the presence of bacteraemia due 
to Gram-negative bacilli and including an amino­
glycoside in the regimen should be considered in spite 
of the increased risk of nephrotoxicity.
Adapting the initial regimen will be the rule rather 
than  exception in patients with prolonged neutro­
penia and a clinically defined infection, which is not 
surprising as it is virtually impossible to cover empiri­
Empirical regimen
Ceftazidime
Avoid this class of drugs
Avoid drugs with high sodium contents
Ceftazidime
Specifically targetted prophylaxis 
Selection on the basis of susceptibility
Wait for culture results 
Ceftazidime
Meropen em/pip eracillin-tazob a ctam 
Ceftazidime
Early addition of an antifungal agent 
Meropenem/ceftazidime but consider adding a glycopeptide 
Ceftazidime 
Meropenem
cally every conceivable pathogen during the entire 
neutropenic episodes. Patients with an obvious focus 
of infection clearly represent a population that is 
more difficult to treat than do those without any focus 
at all [24,25]. It is generally acknowledged that 
patients with a lower respiratory tract infection 
respond poorly to standard empirical regimens, not at 
least because as many as 50% of infiltrates may be 
due to causes other than bacterial infection. 
Treatment failures are also commonly encountered in 
patients with skin and soft-tissue infections that are 
increasingly seen in relation to Hickman's right atrial 
tunnelled catheter. However, considering these infec­
tions are rarely fatal, the addition of a glycopeptide is 
only reasonable when there is a poor response to 
empirical therapy [26], Viridans streptococci origi­
nating from the oral cavity have emerged as the 
leading cause of bacteraemia in patients with chemo­
therapy-induced mucositis. Adult respiratory distress 
syndrome will occur in approximately 10% of 
patients with bacteraemia due to Streptococcus mitis 
but not Streptococcus oralis particularly after high- 
dose cytarabine and proves fatal in approximately 
60% of cases, These so-called4alpha-strep syndromes’ 
are almost certainly multifactorial in origin and the 
streptococcal infection probably triggers off sepsis 
syndrome when there is pre-existing tissue damage 
and alteration in the systemic or local immunity. 
Therefore, corticosteroids rather than supplementary
© 1997 Blackwell Science Ltd Journal of Internal Medicine 242  (Supplement 740): 69-77
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antibiotics should be considered to manage patients 
affected by this complication [2 7], In many cases pre­
mature modifications are made because of continu­
ing fever without there being any evidence of clinical 
deterioration or development of a defined site of infec­
tion. This probably reflects either a lack of confidence 
on the part of the attending physician or an attitude 
that is driven by the belief that ‘it is better to be safe 
now than sorry later’. Either reason gives cause for 
concern because, rather than improving outcome, 
the liberal use of antibiotics actually increases the risk 
of organ toxicity, the development of resistance and 
superinfection, and excessive costs [28]. Conse­
quently, a planned-progressive approach to antibiotic 
therapy involving adjusting the regimen every 2-3 
days according to a predetermined schedule until the 
patient becomes afebrile seems ill advised. It ignores 
the individual differences between different febrile 
neutropenic patients and the fact that further infec­
tions can and do occur. Instead, an individually 
tailored approach to therapy of the febrile neutro­
penic patients such as we propose, seems more 
rational and might prove more cost-effective if this 
were confirmed in a formal clinical trial.
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